NCT02558153已完成不适用
A Randomized Trial of Aperto Paclitaxel Eluting Dilatation Catheter Compared to POBA in Dialysis Fistula
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 105
- 试验地点
- 20
- 主要终点
- Adequate functioning of the hemodialysis access
研究概览
简要总结
A multicenter randomized clinical trial of paclitaxel drug-eluting balloon (DEB) versus standard percutaneous transluminal angioplasty (PTA) to reduce restenosis in 150 patients with haemodialysis access stenoses.
详细描述
Prospective multicenter randomized (1:1) Investigator Sponsored Trial, in which 150 consecutive patients candidates for percutaneous intervention of haemodialysis access will be randomly assigned to one of two study arms:
- Treatment Arm: paclitaxel drug-eluting balloon (DEB) dilatation using the APERTO-balloon
- Control Arm: standard percutaneous transluminal angioplasty (PTA).
The aim is to evaluate the safety and efficacy of paclitaxel drug-eluting balloon (DEB) for the reduction of restenosis in haemodialysis shunts compared to standard percutaneous transluminal angioplasty (PTA).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Outcomes Assessor)
入排标准
- 年龄范围
- 19 Years 至 90 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •All criteria 1-10 must apply for inclusion.
- •Age > 18 years and < 90 years
- •Patient or legally authorized representative providing written informed consent
- •Patient willing and likely to comply with the follow up schedule
- •Patients with previously well functioning hemodialysis access on the arm presenting with any of the following clinical abnormalities as defined in the NKF-DOQI-protocol criteria (National Kidney Foundation 2000):
- •Abnormal physical examination findings (change in bruits, thrill, pulse, etc
- •Abnormal urea recirculation measurements
- •Elevated venous pressure during dialysis
- •Decreased access flow
- •Previous thrombosis in the access line
- •Development of collateral veins
- •Limb swelling
- •Low arterial pressure during dialysis
- •Unexplained decreases in dialysis dose
- •Target Lesion is hemodynamically relevant and consists of MLD ≤ 3 mm. For enrolment this criterium is judged by the local investigator. For final analysis this criterium is based on the result of central reading of the angiogram.
- •Target Lesion(s) is a de-novo or (non-stent) restenosis
- •Target lesion(s) in dialysis fistulas is located at the anastomosis or in the outflow venous trajectory up to the level (but excluding) the subclavian vein
- •Target lesion(s) in dialysis grafts is located at the arterial or venous anastomosis, inside the graft, or in the outflow venous trajectory up to the level (but excluding) the subclavian vein
- •Multiple Target Lesions are allowed per patient which can be treated by a number of APERTO DEB with aggregate max length of 160 mm
- •NON Target Lesions (i.e. in the subclavian vein) must be successfully treated with standard PTA prior to the Target Lesion.
排除标准
- •None of criteria 1-12 must apply for inclusion.
- •Patients unable to give informed consent
- •Patients enrolled in another study with any investigational drug or device
- •Patients previously enrolled in the APERTO trial.
- •Female patients of child bearing potential without a negative pregnancy test at the time of intervention
- •Major surgical procedures within 30 days prior to this study or planned within 30 days of entry into this study
- •Patients previously treated with a DEB in the hemodialysis access.
- •Patients with a trombosed hemodialysis access.
- •Immature hemodialysis access (unusable due to insufficient shunt flow volume)
- •Lesion treated within 30 days prior to screening
- •Failure to successfully treat non-target lesions prior the Target Lesion
- •In stent restenosis
- •Patients with any known allergy, hypersensitivity or intolerance to ASA, clopidogrel or ticlopidine, paclitaxel, or contrast medium.
- •Graft infection
- •Life expectancy < 1 years
结局指标
主要结局
Adequate functioning of the hemodialysis access
时间窗: 12 months
Period of adequate functioning of the hemodialysis access after treatment, defined according to the NKF-DOQI protocol criteria
次要结局
- Clinically driven Target Shunt Revascularization (TSR)(12 months)
- Technical Success(index procedure (day 0))
- MAE - major adverse events(12 months)
- Clinical Success(12 months)
- thrombotic occlusion of target lesion(12 months)
- device success(index procedure (day 0))
- Procedural Success(Index procedure (day 0))
- Clinically driven Target Lesion Revascularization (TLR)(12 months)
- thrombotic occlusion of target hemodialysis access(12 months)
研究者
Dr Peter M.T. Pattynama
MD, PhD. Interventional radiologist
Groene Hart Ziekenhuis
研究点 (20)
Loading locations...
相似试验
终止
2 期
Drug Eluting Balloon Angioplasty for Recurrent Cephalic Arch Stenosis in Dialysis FistulasDialysis Access DysfunctionNCT02368197Shaare Zedek Medical Center13
已完成
4 期
Efficacy Study of Paclitaxel-eluting Balloon, -Stent vs. Plain Angioplasty for Drug-eluting Stent RestenosisHeart DiseaseIschemiaRestenosisNCT00987324Deutsches Herzzentrum Muenchen402
已完成
4 期
Drug Eluting Balloon Angioplasty Versus Nitinol Stent Implantation in the Superficial Femoral ArteryArterial Occlusive DiseasesCardiovascular DiseasesPeripheral Vascular DiseasesPaclitaxelPlaque, AtheroscleroticAtherosclerosisCritical Limb IschemiaPeripheral Arterial DiseaseArteriosclerosisNCT02212470Instituto Dante Pazzanese de Cardiologia85
已完成
不适用
Compare the Efficacy and Safety of RESTORE DEB and SeQuent® Please in Chinese Patient With Coronary In-stent RestenosisCoronary RestenosisNCT02944890ZhuHai Cardionovum Medical Device Co., Ltd.242
Unknown
4 期
Paclitaxel Eluting Balloon and Conventional Balloon for In-Stent Restenosis of the Superficial Femoral ArteryPeripheral Vascular DiseaseNCT01083394Deutsches Herzzentrum Muenchen70